Skip to main content

Elopag 20 mg ( Eltrombopag)

Elopag is identified on this website as a product containing eltrombopag in a stated 20 mg strength. Eltrombopag is an oral prescription medicine used in selected patients with certain conditions associated with low platelet counts or impaired blood-cell production.

Correct dosage and administration are important for achieving the intended treatment response while reducing the risk of complications. The appropriate dose depends on the medical condition, age, liver function, platelet count, previous treatment response and other individual factors.

There is no single dose of eltrombopag that is appropriate for every patient. A 20 mg product strength does not automatically mean that every patient should take one tablet daily. The prescribed dose must be determined by a qualified healthcare professional using the applicable product information.

1. What Is the Recommended Elopag Dose?

The appropriate dose of eltrombopag varies according to the condition being treated.

Different treatment indications have different dosing recommendations. For example, dosing for chronic immune thrombocytopenia may differ from dosing for severe aplastic anemia or thrombocytopenia associated with chronic hepatitis C.

The healthcare professional considers several factors before selecting a dose:

  • The patient’s diagnosis.
  • The patient’s age and body weight, where relevant.
  • Baseline platelet count.
  • Liver function.
  • Previous treatment history.
  • Response to eltrombopag.
  • Other medicines being taken.
  • The applicable prescribing information.

The objective is to achieve the treatment goal using the lowest appropriate dose under the relevant prescribing guidance. In patients with ITP, for example, the aim is generally to maintain a platelet count sufficient to reduce bleeding risk, rather than to increase it unnecessarily to a normal level.

2. Eltrombopag Dosage Depends on the Medical Condition

The following examples describe dosing approaches in U.S. prescribing information for the reference medicine PROMACTA. They are provided as general clinical context and are not an individualized Elopag prescription. Doses and approved indications may differ by country and product.

Chronic or Persistent Immune Thrombocytopenia

For most adults and children aged 6 years and older, the U.S. reference prescribing information describes an initial dose of 50 mg once daily.

For children aged 1 to 5 years, the described initial dose is 25 mg once daily.

Lower initial doses or adjustments may be necessary in certain patients, including some people with liver impairment or patients of East or Southeast Asian ancestry.

The dose is adjusted according to platelet-count response. The reference label specifies a maximum daily dose of 75 mg for this indication.

Chronic Hepatitis C-Associated Thrombocytopenia

For selected patients with chronic hepatitis C-associated thrombocytopenia in the applicable interferon-based treatment setting, the U.S. reference prescribing information describes an initial dose of 25 mg once daily.

The dose may be adjusted according to platelet counts and the requirements of antiviral treatment. The reference label specifies a maximum daily dose of 100 mg.

This should not be interpreted as a general recommendation to use eltrombopag for all patients with hepatitis C or thrombocytopenia.

Severe Aplastic Anemia

Eltrombopag may be used in specific severe aplastic anemia treatment settings.

The dosage depends on whether the medicine is being used alongside initial immunosuppressive treatment or for disease that has not responded adequately to previous immunosuppressive therapy.

Age, body weight, liver function, ancestry-related dose considerations and treatment response may affect the prescribed regimen.

Because severe aplastic anemia is a serious bone marrow disorder, treatment should be managed by an appropriate specialist.

3. Is Elopag 20 mg Taken Once Daily?

Eltrombopag is commonly administered once daily in the treatment settings described in its prescribing information. However, the exact prescribed dose and schedule depend on the medical indication and individual patient factors.

A product strength of 20 mg represents the amount of active ingredient stated for that product. It does not establish the correct number of tablets or the frequency of administration.

Patients should not assume that taking one 20 mg tablet daily is appropriate simply because the product is labeled 20 mg.

Follow the prescription and the official leaflet supplied with the specific product.

4. How to Take Elopag

Eltrombopag is taken by mouth. If the prescribed Elopag product is a tablet, it should be swallowed according to its official product instructions.

For reference, the U.S. PROMACTA prescribing information provides the following tablet-administration precautions:

  • Take the tablet without a meal or with a meal containing no more than 50 mg of calcium.
  • Take it at least 2 hours before or 4 hours after certain medicines, foods or supplements containing polyvalent cations.
  • Do not split, chew or crush the tablet.
  • Do not mix a tablet with food or liquid.

Patients should follow the instructions for their own product because formulations and approved administration instructions may differ.

5. Should Elopag Be Taken Before or After Food?

Food can affect the absorption of eltrombopag.

The U.S. reference prescribing information recommends taking PROMACTA without a meal or with a meal low in calcium, defined as 50 mg of calcium or less.

Calcium-rich foods may reduce how much eltrombopag is absorbed into the bloodstream. Examples include:

  • Milk.
  • Cheese.
  • Yogurt.
  • Calcium-fortified fruit juices.
  • Certain calcium-rich foods.

The exact meal instructions should be checked against the official leaflet for the prescribed product.

Patients should avoid changing their eating or medicine schedule without understanding the product-specific instructions.

6. Medicines and Supplements to Separate From Eltrombopag

Eltrombopag can interact with products containing polyvalent cations. These substances may bind to the medicine in the digestive tract and reduce its absorption.

Examples include products containing:

  • Calcium.
  • Iron.
  • Magnesium.
  • Aluminium.
  • Zinc.
  • Selenium.

Some antacids and mineral supplements contain these ingredients. Certain fortified foods and drinks may also contain significant amounts of calcium.

The U.S. reference prescribing information recommends taking PROMACTA at least 2 hours before or 4 hours after medicines and products containing these substances.

Patients should ask their pharmacist to help organize a suitable daily schedule, especially if they take several medicines or supplements.

7. What Time Should Elopag Be Taken?

Eltrombopag is generally taken once daily in the treatment settings described in its prescribing information.

Taking the medicine at a consistent time may help patients follow their prescribed schedule. However, the timing must also account for food and interactions with mineral-containing products.

A healthcare professional or pharmacist can help establish a routine that fits the patient’s prescription, meals and other medicines.

Do not take an additional dose simply because the medicine was taken later than usual.

8. What Should You Do If You Miss a Dose?

If you miss a dose of eltrombopag, follow the instructions in the official product leaflet or ask a pharmacist or prescribing healthcare professional what to do.

Do not take an extra dose to compensate for a missed dose unless specifically instructed by your healthcare professional.

Taking more than prescribed may increase the risk of excessive platelet counts and other complications.

Patients who frequently forget doses may benefit from a medicine schedule or reminder system.

9. What Happens If You Take Too Much Elopag?

Taking more eltrombopag than prescribed may cause platelet counts to rise excessively.

An excessive increase in platelet counts can increase the risk of blood clots and other complications.

If an overdose is suspected, contact an appropriate healthcare professional or poison information service promptly. Seek emergency medical care if serious symptoms occur.

Do not wait for symptoms to develop before seeking advice about a suspected overdose.

10. Monitoring During Elopag Treatment

Regular monitoring is an important part of eltrombopag treatment.

Platelet Count

Platelet-count testing helps the healthcare professional evaluate whether the medicine is working and whether the dose needs adjustment.

Monitoring can also identify platelet counts that have increased excessively.

Liver Function Tests

Eltrombopag can cause liver-related abnormalities and potentially serious liver injury.

Liver function should be assessed before and during treatment according to the applicable prescribing information.

Tests may include ALT, AST and bilirubin measurements.

Other Blood Tests

Depending on the underlying condition, additional blood tests may be needed to evaluate treatment response and overall blood-cell production.

Patients with severe aplastic anemia may require particularly careful monitoring because the condition can affect red blood cells, white blood cells and platelets.

Monitoring After Stopping Treatment

Platelet counts may decrease after eltrombopag is discontinued. Healthcare professionals may therefore recommend continued blood-count monitoring after treatment ends.

Patients should not stop treatment without professional guidance.

11. Important Precautions Before Taking Elopag

Before starting treatment, inform the healthcare professional about:

  • Existing liver disease.
  • Previous blood clots.
  • A history of bleeding problems.
  • Other blood or bone marrow disorders.
  • Pregnancy or plans to become pregnant.
  • Breastfeeding.
  • All prescription and nonprescription medicines.
  • Vitamins, minerals and herbal supplements.
  • Previous allergic reactions to medicines.

This information helps the healthcare professional assess treatment suitability and identify possible risks.

12. Can the Elopag Dose Be Changed?

Dose changes may be necessary during eltrombopag treatment. They are generally based on platelet counts, treatment response, adverse reactions and the patient’s medical condition.

A healthcare professional may decide to increase, reduce, interrupt or discontinue treatment depending on the clinical situation.

Patients should never make these changes independently.

A dose that is appropriate for one patient may not be appropriate for another, even when both patients have the same diagnosis.

13. Important Safety Information

Eltrombopag can cause adverse reactions, some of which may require medical attention.

Important safety concerns include:

Liver injury: Eltrombopag may cause liver-function abnormalities or serious hepatotoxicity. Patients should attend recommended liver-function tests.

Blood clots: Excessively high platelet counts may increase the risk of thrombotic or thromboembolic complications.

Bleeding after discontinuation: Platelet counts may fall after treatment is stopped, potentially increasing bleeding risk in some patients.

Other adverse reactions: Nausea, diarrhea, headache, fatigue and other reactions have been reported in eltrombopag treatment settings.

Seek medical attention for severe or unusual symptoms. Sudden chest pain, difficulty breathing, sudden weakness or uncontrolled bleeding require urgent assessment.

14. Elopag 20 mg Product-Specific Information

The stated strength of Elopag on this website is 20 mg. However, the specific product’s manufacturer, formulation and country-specific prescribing instructions have not been independently confirmed for this page.

Before using the product, verify:

  • The active ingredient.
  • The stated strength.
  • The dosage form.
  • The manufacturer’s name.
  • The batch number.
  • The expiry date.
  • The official patient leaflet.
  • Applicable regulatory authorization.

Do not assume that instructions for a different eltrombopag brand or formulation automatically apply to Elopag.

Frequently Asked Questions

How often is Elopag taken?

Eltrombopag is commonly prescribed once daily in several treatment settings. The exact schedule depends on the patient’s condition and prescription.

Should Elopag 20 mg be taken before or after food?

The U.S. reference prescribing information recommends taking PROMACTA without a meal or with a meal containing no more than 50 mg of calcium. Check the official instructions for the specific Elopag product.

Can I take Elopag with milk?

Calcium-rich foods, including milk, may reduce eltrombopag absorption. Follow the required separation instructions in the applicable product leaflet.

Can I take calcium or iron supplements with eltrombopag?

These supplements may interfere with absorption. The U.S. reference prescribing information recommends separating PROMACTA from products containing polyvalent cations by at least 2 hours before or 4 hours after.

What should I do if I miss a dose?

Follow the official missed-dose instructions or contact a pharmacist. Do not take an extra dose to make up for a missed one unless instructed by a healthcare professional.

Can I increase my dose if my platelet count remains low?

No. Dose adjustments must be based on laboratory results and clinical assessment by the prescribing healthcare professional.

Do I need blood tests while taking Elopag?

Yes. Platelet counts and liver function may need regular monitoring. Other tests may be required depending on the underlying condition.

Can I stop Elopag when my platelet count improves?

Do not stop treatment independently. Platelet counts may fall after eltrombopag is discontinued, so the decision should be made by the prescribing healthcare professional.

Medical Disclaimer

This page provides general educational information about eltrombopag dosage and administration. It does not provide an individualized prescription or replace the official prescribing information for a specific product.

The dosage examples in this content are based on U.S. reference prescribing information and may not apply to every country or eltrombopag product.

Always follow the prescription and official leaflet supplied with your medicine. Consult a qualified healthcare professional before starting, stopping or changing treatment.

References

  • U.S. Food and Drug Administration, PROMACTA (eltrombopag) Prescribing Information, revised June 2025.
  • U.S. National Library of Medicine, DailyMed, PROMACTA prescribing information.
  • Applicable national medicines regulatory authority product information.

Product-specific note: The dosage of Elopag 20 mg must be confirmed against its own official prescribing information. The strength alone does not establish the appropriate patient dose.